Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

Name:  Ward:  NHI:  Epoetin alfa  INITIATION – chronic renal failure  Prerequisites (tick boxes where appropriate)  Patient in chronic renal failure  Haemoglobin is less than or equal to 100g/L  and		
INITIATION – chronic renal failure Prerequisites (tick boxes where appropriate)  O Patient in chronic renal failure and Haemoglobin is less than or equal to 100g/L		
INITIATION – chronic renal failure  Prerequisites (tick boxes where appropriate)  O Patient in chronic renal failure and Haemoglobin is less than or equal to 100g/L		
Prerequisites (tick boxes where appropriate)  O Patient in chronic renal failure and Haemoglobin is less than or equal to 100g/L		
And O Haemoglobin is less than or equal to 100g/L		
O Haemoglobin is less than or equal to 100g/L		
Patient does not have diabetes mellitus  and Glomerular filtration rate is less than or equal to 30ml/min		
Or Patient has diabetes mellitus		
O Glomerular filtration rate is less than or equal to 45ml/min		
O Patient is on haemodialysis or peritoneal dialysis		
INITIATION – myelodysplasia* Re-assessment required after 2 months Prerequisites (tick boxes where appropriate)		
O Patient has a confirmed diagnosis of myelodysplasia (MDS) and		
Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent and		
Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplasis syndrome (WPSS)		
Other causes of anaemia such as B12 and folate deficiency have been excluded and		
Patient has a serum epoetin level of < 500 IU/L		
The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week		
CONTINUATION – myelodysplasia* Re-assessment required after 12 months Prerequisites (tick boxes where appropriate)		
The patient's transfusion requirement continues to be reduced with epoetin treatment and _		
Transformation to acute myeloid leukaemia has not occurred and		
The minimum necessary dose of epoetin would be used and will not exceed 80,000 iu per week		

I confirm that the above details are correct:

Signed: ...... Date: .....

## HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:
Name:	Name:
Ward:	NHI:
Epoetin alfa - continued	
INITIATION – all other indications  Prerequisites (tick box where appropriate)  O Prescribed by, or recommended by a haematologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.  and O For use in patients where blood transfusion is not a viable treatment alternative  Note: Indications marked with * are unapproved indications	